CEL-SCI prices $10 million public offering at $9 per share

CEL-SCI Corporation (NYSE American: CVM) announced the pricing of a public offering of 1,111,200 shares of common stock at $9.00 per share. The clinical-stage cancer immunotherapy company expects to raise approximately $10 million in gross proceeds before deducting placement agent fees and other offering expenses.

The offering is scheduled to close on August 29, 2025, subject to customary closing conditions. ThinkEquity serves as the sole placement agent for the transaction.

The company plans to use net proceeds to fund continued development of Multikine, its investigational cancer immunotherapy, along with general corporate purposes and working capital needs.

The securities are being offered under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on July 3, 2025, and declared effective on August 12, 2025.

Multikine is designed as a neoadjuvant therapy administered before surgery to help patients' immune systems target tumors. The treatment has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.

CEL-SCI operates facilities in Vienna, Virginia, and the Baltimore, Maryland area. The information is based on a company press release.

You May Also Be Interested In

• Aveanna Healthcare prices secondary offering at $11.75 per share
• ESS Tech launches $3.2M stock offering at $0.50 per share
• EShallGo closes $1.75M registered direct offering at $1 per share